Stockscreener 앱 받기
345.82
0.25%
0.86
시간 외 거래:
345.82
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo! Finance Canada
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
KRYS Reinstated by Goldman Sachs -- Price Target Announced at $4 - gurufocus.com
Krystal Biotech stock initiated at buy by Goldman Sachs - Investing.com Nigeria
KRYS Looks 0.1% Overvalued on GF Value™ - gurufocus.com
Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441 - Moomoo
Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones - Stock Traders Daily
KRYS Maintained by B of A Securities -- Price Target Raised to $400 - gurufocus.com
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400 - Moomoo
KRYSTAL BIOTECH, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $400 FROM $392 - Bitget
BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Look At Its 14.36% Potential Upside - DirectorsTalk Interviews
Krystal Biotech (NASDAQ: KRYS) Grants Director Sutherland Everett Rand 1,658 Derivative Securities - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Catherine Mazzacco - Kalkine Media
Rossi Dino A Granted 1,658 Derivative Securities of Krystal Biotech, Inc. on September 14, 2026 - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Mason Christopher - Kalkine Media
Director at Krystal Biotech (KRYS) gets new stock options and RSUs - Stock Titan
Krystal Biotech (KRYS) board member receives new options and RSUs - Stock Titan
Krystal Biotech | 4: Statement of changes in beneficial ownership of securities-Director ROSSI DINO A - Moomoo
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Put Krystal Biotech (KRYS) in Focus? - Kalkine Media
Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada
KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView
Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - kalkinemedia.com
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de
Krystal Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Eastern Progress
Krystal Biotech Inc (MIL:1KRYS) Stock Price, Trades & News - GuruFocus
3.06%
2.55%
자본화:
|
볼륨(24시간):